Actinium Announces Positive Top-line Results from Pivotal Phase 3 SIERRA Trial of Iomab-B in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia

/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today...

Related Keywords

United States ,American ,Hans Vitzthum ,Lifesci Advisors ,International Blood Marrow Transplant Research ,American Society Of Hematology ,Astellas Pharma Inc ,Actinium Pharmaceuticals Inc ,Oncology Inc ,Epicentrx Inc ,Society Of Hematologic Oncology ,Memorial Sloan Kettering Cancer Center ,Fred Hutchinson Cancer Research Center ,Actinium Pharmaceuticals ,Elderly Relapsed ,Bone Marrow Transplant ,About Iomab B ,Pivotal Phase ,Complete Remission ,About Actinium Pharmaceuticals ,Refractory Acute Myeloid Leukemia ,American Society ,Tandem Meetings ,Cellular Therapy Meetings ,Cellular Therapy ,International Blood ,Marrow Transplant Research ,Hematologic Oncology ,Acute Myeloid Leukemia ,Astellas Pharma ,Sci Advisors ,Nc ,